Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Status:
Recruiting
Trial end date:
2022-08-13
Target enrollment:
Participant gender:
Summary
The investigators will recruit 15 patients with cystic fibrosis 18 years of age and older who
present with constipation. The investigators will assess baseline motility symptoms with a
survey. Patients will then ingest a SmartPill (trademark) to obtain baseline motility within
the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or
Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat
the motility survey and again ingest a smart pill to assess the change in motility symptoms
while on therapy.